Complete response of brain metastases from breast cancer overexpressing HER-2/neu to radiation and concurrent Lapatinib and Capecitabine

Breast Journal

Volumn 16, Issue 6, 2010, Pages 644-646

  Abboud, Mirna ^a   Saghir, Nagi S El ^a   Salame, Joseph ^a   Geara, Fady B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

brain radiation; breast cancer; complete response; HER 2 overexpression; Lapatinib

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ADULT; ANAMNESIS; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; FEMALE; FOLLOW UP; HUMAN; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; QUINAZOLINES; RADIOTHERAPY DOSAGE; RECEPTOR, ERBB-2;

EID: 78449280747     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.00980.x     Document Type: Article

References (17)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-44.
3. Pestalozzi BC, Brignoli S,. Trastuzumab in CSF. J Clin Oncol 2000; 18: 2349-51.
4. Stemmler J, Schmitt M, Willems A, Berhard H, Harbeck N, Heinemann V,. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18: 23-8.
5. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17: 952-6.
6. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107: 1348-54.
7. Oberhoff C, Kieback DG, Wurstlein R, et al. Effectiveness and tolerance of primary topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Proc Am Soc Clin Oncol 2001; 20:72b. (abstr 2036).
8. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004; 22: 196. (suppl; abstr 3006).
9. Stewart DJ, Molepo JM, Green RM, et al. Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 1995; 71: 598-604.
10. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100: 1092-103.
11. Lin N, Carey L, Liu M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26: 1993-9.
12. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004; 22: 196s. (suppl; abstr 3006).
13. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
14. Lin N, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15: 1452-9.
15. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ,. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347-55.
16. Harari PM, Huang SM,. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 2001; 11: 281-9.
17. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI,. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004; 58: 344-52.